RC
GLUE icon

Rangeley Capital’s Monte Rosa Therapeutics GLUE Stock Holding History

Rangeley Capital’s Portfolio GLUE Stock Details GLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$444K Sell
27,016
-40,484
-60% -$774K 0.43% 49
2025
Q4 		$1.06M Sell
67,500
-45,500
-40% -$613K 0.88% 37
2025
Q3 		$837K Buy
+113,000
New +$598K 0.72% 35

Other funds holding GLUE

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Rangeley Capital's GLUE Position: Q1 2026 in Review

Rangeley Capital reduced its Monte Rosa Therapeutics (GLUE) stake by 60% in Q1 2026, selling an estimated $774K and leaving 27,016 shares worth $444K. The position accounts for 0.43% of the portfolio, ranked #49.

Rangeley Capital first reported a position in GLUE in Q3 2025 and has held it in 3 quarters since. The position peaked at $1.06M in Q4 2025. 190 funds tracked by Wall St. Rank hold GLUE as of Q1 2026.

  • Rangeley Capital held 27,016 shares of Monte Rosa Therapeutics worth $444K as of Q1 2026.
  • Rangeley Capital sold 40,484 Monte Rosa Therapeutics shares in Q1 2026, an estimated $774K.
  • Monte Rosa Therapeutics made up 0.43% of Rangeley Capital's portfolio in Q1 2026, its #49 holding.
  • Rangeley Capital first reported a position in Monte Rosa Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • Rangeley Capital's Monte Rosa Therapeutics position peaked at $1.06M in Q4 2025.
  • 190 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q1 2026.

Based on Rangeley Capital's 13F filing for Q1 2026, filed 15 May 2026.